





Patent Application  
Attorney Docket No. PC10434B

RECEIVED  
APR 09 2003  
TECHNICAL SERVICES  
1600/2990

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231 on this 2nd day of April 2003.

By

(Signature of person mailing)

A. David Joran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Harry Ralph Howard :

APPLICATION NO.: 09/845,992 : Examiner: Saeed, K. A.

FILING DATE: April 30, 2001 : Group Art Unit: 1626

TITLE: MONOAMINE REUPTAKE :  
INHIBITORS FOR TREATMENT OF  
CNS DISORDERS

Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 (c) (1) AND  
CERTIFICATE UNDER 37 CFR §1.97 (e) (1)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Since the references cited were cited in a communication from a foreign patent office in connection with a counterpart application not more than three months prior to this statement, no fee is believed to be due. However, if a fee is deemed to be due, the Commissioner is hereby authorized to charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.


CERTIFICATE UNDER 37 CFR § 1.97 (e) (1)

Applicants' undersigned attorney avers that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Information Disclosure Statement.

Date: \_\_\_\_\_

Apr. 2, 2003

Respectfully submitted,

  
\_\_\_\_\_  
A. David Joran  
Attorney for Applicant(s)  
Reg. No. 37,858

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -3381